How many investments has HEALTHCARE ROYALTY PARTNERS made?

HEALTHCARE ROYALTY PARTNERS has 81 tracked investments, 13 of which have exited, including 1 dated in the last 24 months.

What sectors does HEALTHCARE ROYALTY PARTNERS focus on?

HEALTHCARE ROYALTY PARTNERS focuses on Biotech, Healthtech.

Where is HEALTHCARE ROYALTY PARTNERS located?

HEALTHCARE ROYALTY PARTNERS is headquartered in New York, US.

Who does HEALTHCARE ROYALTY PARTNERS co-invest with?

HEALTHCARE ROYALTY PARTNERS most often shares deals with Foresite Capital, New Enterprise Associates (NEA), Ridgeback Capital, among 44 tracked co-investors.

HEALTHCARE ROYALTY PARTNERS

Venture debt

New York · 29 people tracked

Also known as HEALTHCARE ROYALTY MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into HEALTHCARE ROYALTY PARTNERS

Each arrow is one introduction. Sign up to fill in the first one.

512 people can intro you to John

Ask Greg Brown to introduce you to John A. Urquhart

You →Greg · together at HEALTHCARE ROYALTY PARTNERS →John

264 people can intro you to Clarke

Ask Jamie Chen to introduce you to Clarke B. Futch

You →Jamie · together at Paul Capital Partners →Clarke

108 people can intro you to Warren

Ask Sam Okafor to introduce you to Warren D. Cooper

You →Sam · together at Nutrition 21, Inc. →Warren

Carlos M. Almodóvar5 people can intro you
Evan Bograd5 people can intro you
Thomas K. Conner5 people can intro you

Your email: who you already know at HEALTHCARE ROYALTY PARTNERS, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the HEALTHCARE ROYALTY PARTNERS team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict

Investment thesis

HCRx focuses on advancing biopharmaceutical innovation through creative capital solutions, principally royalty monetization and corporate financing arrangements for life sciences and biopharma companies. Since inception the firm has committed more than $7 billion across over 110 biopharma products, supporting companies that develop and commercialize approved and near-approval therapeutics. Its financing model provides non-dilutive capital tied to product revenues and royalty streams rather than traditional early-stage venture equity.

Invests inBiotech Healthtech New York Stamford United Kingdom United States

Source: firm website, verified Sep 29, 2026.

Leave your own feedback

New York, US

Instruments

Debt

Founded

2016

AUM

$3.8B

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 29 people

from the firm's website & public directories

Clarke B. Futch· Chairman and Chief Executive Officer· New York City Metropolitan Areain

Clarke B. Futch is Chairman and CEO of HCRx, where he sets the firm's strategic direction and evaluates new opportunities. Since 2001 he has led or co-led over 100 royalty-related acquisitions and has over 30 years of experience in biopharmaceutical and healthcare investing and financing. He previously was a partner at Paul Capital Partners, a founding member of the healthcare group at Thomas Weisel Partners (now Stifel), and a vice president at Raymond James. He holds a BA from Vanderbilt University and a JD from the University of Virginia School of Law.

John A. Urquhart· Senior Managing Director· Bostonin

John A. Urquhart is a Senior Managing Director and Investment Committee member at HCRx, where he leads the firm's New England activities including transaction sourcing and structuring. He has over a decade of healthcare investing experience in the royalty and debt markets, and has worked on 21 investments since 2012, serving as lead on 13 of them. Before joining HCRx in 2007 as HCR's first employee, he was an investment banking analyst at Cowen and Company, and he holds a BA from Brown University and an MBA from The Wharton School.

Joshua C. House· Managing Director

Aaron B. Simon· Associate· New York City Metropolitan Areain

Amy J. Zacharias· Senior Vice President and Controller

Andrew Logerfo· Vice President· United Statesin

Andrew Logerfo is a Vice President at HCRx, where he supports transaction-related activities such as financial analysis, transaction structuring, and due diligence, and contributes to business development. He previously worked in the healthcare investment banking group at BMO Capital Markets, focusing on M&A and capital raising for biopharma companies. He holds an MBA from Columbia Business School and a BA in Government from Georgetown University.

Carlos M. Almodóvar· Chief Business Officer

Carlos M. Almodóvar is Chief Business Officer at HCRx, where he leads the firm's fundraising and supports strategic initiatives. He previously worked in business development at Strategic Value Partners, an alternative investment firm focused on distressed debt, and served as an associate director at UBS raising capital for external private fund managers, having started his career as an analyst in Lehman Brothers' real estate investment banking group. He holds a BS from Cornell University.

Christopher A. White· President and Chief Financial Officer· Springfield, Massachusetts Metropolitan Area

Christopher A. White is President, CFO, and a member of the Investment Committee at HCRx, which he rejoined in 2015 after previously serving on the committee as a Cowen, Inc. representative from the firm's inception through 2011. His responsibilities include the firm's origination and sourcing function as well as strategic and operational aspects of the business. Earlier in his career he was managing director and head of investment banking at Janney Montgomery Scott, held senior management roles at Cowen, and worked at Salomon Smith Barney and as a securities and M&A lawyer. He holds a BA from Amherst College and a JD from the University of Michigan Law School.

David Oron· Analyst

David Oron is an Analyst at HCRx, where he supports transaction-related work including financial analysis, transaction structuring, due diligence, and business development. He previously worked as a strategy consultant at Putnam, advising biopharma clients on commercial and access strategy. He holds a BS in Biomedical Engineering from Cornell University.

Eric Yoo· Vice President

Eric Yoo is a Vice President at HCRx, where he mainly supports research and also contributes to business development and transaction work such as financial analysis, transaction structuring, and due diligence. He previously was Director of Research & Investments at DRI Healthcare (DRI Capital), a biotechnology equity research analyst at Stifel Europe in London covering European SMID-cap biotech, and an investment analyst at Third Eye Asset Management. He holds a PharmD and a BSc from the University of Waterloo.

Evan Bograd· Vice President

Evan Bograd is a Vice President at HCRx, where he supports transaction-related activities such as financial analysis, transaction structuring, and due diligence, and participates in business development. He previously worked in the healthcare investment banking practices of Bank of America and Mizuho, focusing on M&A and capital raising for biopharma companies. He holds a BA in Economics from Pomona College.

Hayden C.B. Futch· Associate

Jason Dorr· Associate

Jason Dorr is an Associate at HCRx, where he primarily supports research efforts and contributes to business development and transaction work including financial analysis, transaction structuring, and due diligence. He previously worked as a biotechnology equity research associate at Oppenheimer & Co., covering SMID-cap equities in endocrinology, immunology, and orphan diseases, and as a consultant at L.E.K. Consulting advising biotechnology companies. He earned a PharmD from Rutgers University.

Jeffrey Jung· Chief Legal Officer

Lauren C. Dunn· Executive Assistant

Max Serrano-Wu· Analyst

Max Serrano-Wu is an Analyst at HCRx, where he supports transaction-related work such as financial analysis, transaction structuring, and due diligence, as well as business development. Before HCRx, he worked in life science consulting at Trinity Life Sciences, advising biopharmaceutical clients on commercial strategy, market opportunity, competitive landscape, market access, and brand growth. He holds a BA with Honors in Human Developmental and Regenerative Biology from Harvard College.

Michele D. Romaniello· Chief of Staff· Fairfield, Connecticut, United Statesin

Michele D. Romaniello is Chief of Staff at HealthCare Royalty (HCRx), where she oversees the daily operations of the office and manages the administrative team. Her responsibilities also extend to supporting the firm's marketing, business development, and investor relations functions.

Rosa I. Mercado· Finance Clerk

Ryan P. Delaney· Associate

Sean M. McMerriman· Fund Accountant· Boston, Massachusetts, United Statesin

Sean M. McMerriman is a Fund Accountant at HCRx, where he supports the finance and accounting team. He previously worked as a Senior Fund Accountant at Littlejohn & Co., handling accounting for select private equity and distressed funds, and before that as a Senior Assurance Associate in the Asset and Wealth Management group at PricewaterhouseCoopers LLP. He holds a BS in Accounting and Finance from Fairfield University.

Shin W. Kang· Chief Scientific Officer

Shin W. Kang serves as Chief Scientific Officer and Head of Research at HCRx, where he leads research efforts and sourcing tied to universities, research institutions, and inventors, having joined in 2015. Before HCRx, he was a vice president of equity research covering biotechnology at Wells Fargo Securities and previously handled technology, intellectual property, and business development at the Mount Sinai School of Medicine. He holds a PhD in Biological Chemistry/Immunology from UCLA, an MBA from Columbia Business School, and a BS from UC Davis, and completed a postdoctoral fellowship at Genentech.

Spencer H. Schneider· Chief Compliance Officer and Chief Patent Counsel· New York City Metropolitan Areain

Spencer H. Schneider is Chief Compliance Officer and Chief Patent Counsel at HCRx, where he built the firm's compliance program, oversaw its SEC registration as an investment adviser, and handles intellectual property matters within the transaction team. He is a registered patent attorney who previously served as a principal at Speyside Capital Advisors and as a senior lawyer in the IP groups of Dewey & LeBoeuf, Ropes & Gray, and Cooper & Dunham. He earned a BA in Biology from Columbia College, an MS in Biochemistry and Molecular Biology from New York Medical College, and a JD from Cardozo School of Law.

Stephanie A. Gilbey· Executive Assistant

Thomas K. Conner· Chief Accounting Officer and Treasurer

Thomas K. Conner is Chief Accounting Officer and Treasurer at HCRx, where he oversees accounting and finance matters including reporting, financial statement and tax preparation, and cash management. Before HCRx, he spent over twenty years at Cowen & Company, serving as chief financial officer until its merger with Ramius and later as chief operating officer of investment banking, after starting his career at Deloitte Haskins & Sells in 1983. He holds a BBA from the University of Massachusetts, Amherst and is a Certified Public Accountant licensed in New York.

Tolly Flinn· Senior Associate· Fairfield, Connecticut, United Statesin

Tolly Flinn is a Senior Associate at HCRx, where she supports the firm's strategic and business development activities. She previously worked in investment banking at Centerview Partners, focusing on M&A and strategic advisory work for companies across industries. She holds a BA in Economic and Social History from Barnard College, Columbia University.

Warren D. Cooper· Chief Medical Officer· Los Angeles Metropolitan Areain

Warren D. Cooper is Chief Medical Officer at HCRx, where he also heads the Portfolio Management Committee and chairs the Senior Advisor Board, having previously advised the firm. A UK-trained physician with a background in cardiology and cardiac surgery, he spent 12 years at Merck, ultimately leading worldwide clinical research operations for Merck Research Laboratories, and later ran the cardiovascular business division at AstraMerck (now AstraZeneca). He was founding CEO of Prism Pharmaceuticals, which was sold to Baxter International, and holds degrees in physiology, medicine, and surgery from The London Hospital (University of London).

Yichen Wang· Vice President· New York City Metropolitan Areain

Yichen Wang is a Vice President at HCRx, where she primarily supports the firm's research efforts and contributes to business development and transaction activities such as financial analysis, transaction structuring, and due diligence. Before HCRx, she worked as a life science strategy consultant. She holds a PhD in Molecular Biology and Genetics and an MBA from the University of Delaware, and earned her MD as a trained ophthalmologist from Capital Medical University in Beijing, China.

Gregory B Brown, M.D.· Promoter

Todd C Davis· Promoter

What they invest in

from 43 of 81 portfolio companies

Biotech ×41Healthtech ×34Medical Devices ×21Digital Health ×7Deep Tech ×1Fintech ×1

HQs:United States×23France×1Netherlands×1

Who they back

founder profiles across 9 portfolio companies

78%

solo founders

7 of 9 mapped founding teams

Founding team size:solo founder×72 founders×2

Investments · 81 tracked

founders shown can be your intro path

By year:2025 · 1 2022 · 1 2017 · 1 2016 · 1 2014 · 26 dated

ADC Therapeutics SAadctherapeutics.com inNYSE: ADCT

ADC Therapeutics is a biopharmaceutical company that develops antibody drug conjugates and other therapies focused on hematology and oncology.

BiotechHealthtechMedical Devices

Ameet Mallik(Chief Executive Officer)inJose Carmona(Chief Financial Officer)Mohamed Zaki(Chief Medical Officer)in Kristen Harrington-Smith(Chief Commercial Officer)in David Ege(Chief Technical Officer)in Peter Graham(Chief Legal Officer)in

Co-investorsETCapital Scientia Ventures

Agenusagenusbio.comNASDAQ: AGEN

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life Sciences Grazia Equity GmbH Oberland Capital Commodore Capital Invus Ligand Pharmaceuticals +1 more

Apnimedapnimed.com in 𝕏NASDAQ: APMD

Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.

BiotechDigital HealthHealthtechCambridge, US

Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)

Co-investorsAlpha Wave Global Morningside Group Sectoral Asset Management

Aptevo Therapeuticsaptevotherapeutics.comNASDAQ: APVOApr 2025

Aptevo Therapeutics is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies to treat cancer.

BiotechHealthtechSeattle, US

Marvin L. White(Executive Officer, Director)inDaphne Taylor(Executive Officer)Jeffrey G. Lamothe(Executive Vice President and Chief Operating Officer)

BoardJohn E Niederhuber(Director)Daniel J Abdun-Nabi(Director)Grady Grant III(Director)

Co-investorsYorkville Advisors

Atara Biotherapeuticsatarabio.com in 𝕏NASDAQ: ATRA

Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.

BiotechHealthtechMedical DevicesThousand Oaks, US

AnhCo Nguyen(President and Chief Executive Officer)

Co-investorsDag Ventures EcoR1 Capital Kleiner Perkins Domain Associates Fidelity Investments

Coherus Biosciencescoherus.com in 𝕏NASDAQ: CHRS

Coherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer.

BiotechHealthtechMedical DevicesRedwood City, US

Dennis M. Lanfear(Executive Officer, Director)Denny Lanfear(Founder)inAlan C. Herman(Executive Officer)inJean-Frederic Viret, Ph.D.(Executive Officer)Peter K. Watler, Ph.D.(Executive Officer)Barbara K Finck, M.D.(Executive Officer)

Co-investorsF-Prime Capital Sofinnova Ventures Venrock

Nektar Therapeuticsnektar.com inNASDAQ: NKTR

Nektar develops therapies that modulate the immune system to treat autoimmune diseases and inflammatory conditions, targeting the root causes of immune dysfunction.

BiotechHealthtechSan Francisco, US

Howard W. Robin(Executive Officer, Director)Gil M. Labrucherie(Executive Officer)inManinder Hora(Executive Officer)inStephen K. Doberstein(Executive Officer)John Nicholson(Executive Officer)Jillian B. Thomsen(Executive Officer)

Co-investorsNew Enterprise Associates (NEA)

RedHill Biopharma Ltdredhillbio.comNASDAQ: RDHL

BiotechTel Aviv

Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)

Co-investorsLifeSci Venture Partners

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPRO

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)in Stephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

Board Jean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)

Co-investorsGV (Google Ventures)MRL Ventures Fund OUP (Osage University Partners)RA Capital Alphabet Atlas Venture +1 more

AcuFocus, Inc.acufocus.com

BiotechIrvine, US

Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)

BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)

Co-investorsEvidity Health Capital Flying L Partners Revelation Partners SV Life Sciences Versant Venture AIV Holdings Versant Ventures

Adynovateadynovate.com

The site presents ADYNOVATE, a PEGylated recombinant antihemophilic Factor VIII injectable used to treat and control bleeding in adults and children with hemophilia A.

BiotechHealthtech

Albireo Pharmaalbireopharma.com in 𝕏

A biopharmaceutical company (Ipsen, following its acquisition of Albireo Pharma) developing and commercializing medicines in oncology, rare diseases, and neuroscience for patients with high unmet medical needs.

BiotechHealthtech

Co-investorsDecheng Capital

Ardelyxardelyx.com 𝕏

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)inDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)Mike Raab(Executive Officer, Director)in

BoardDavid Mott(Director)

Co-investorsForesite Capital New Enterprise Associates (NEA)

Bridgebiobridgebio.com in 𝕏

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Co-investorsAisling Capital Amzak Health EcoR1 Capital Frazier Life Sciences Longwood Fund Sequoia Capital +2 more

Chiasmachiasmapharma.com

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)in Todd T. Foley(Director)inVincent Miles(Director)Ansbert K. Gadicke(Director)in

Co-investorsSofinnova Ventures Abingworth ARCH Venture Partners MPM BioImpact

Clearside Biomedicalclearsidebio.com in

Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.

BiotechHealthtechMedical DevicesAlpharetta, US

Mark Prausnitz(Director)inCharles Deignan(Executive Officer)Glenn Noronha(Executive Officer)in Daniel H. White(Executive Officer, Director)in

BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in

Co-investorsMountain Group Capital Solasta Ventures Hatteras Hatteras Venture Partners

Curis Inccuris.com in 𝕏

Curis is a biopharmaceutical company focused on drug development and clinical advancement.

BiotechHealthtech

James Dentzer(Chief Executive Officer)

Ebvalloebvallo-ebv.com

EBVALLO is an on-demand allogeneic T-cell immunotherapy for treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.

BiotechDigital HealthMedical Devices

Eligardeligard.com

ELIGARD is a GnRH agonist medication in injectable form used to treat prostate cancer by reducing testosterone production.

BiotechHealthtechMedical Devices

Invuityinvuity.comMar 2014 · $36M

Sophisticated optics for illumination and enhanced visualization in surgical procedures.

HealthtechSan Francisco, US

Kenneth Trauner(Executive Officer, Director)Alex Vayser(Executive Officer)Philip Sawyer(Executive Officer, Director)inTheresa Brandner-Allen(Executive Officer)Brett Robertson(Executive Officer)Doug Rimer(Executive Officer)

Co-investorsAlpine Meridian Windham Capital Partners Avedro, Inc.Kleiner Perkins Valence Advantage Life Sciences Wellington Management

Iqirvoiqirvo.com

IQIRVO is a prescription medicine for treating primary biliary cholangitis (PBC) in adults, used either in combination with ursodeoxycholic acid or as a standalone treatment for patients unable to tolerate standard therapy.

BiotechHealthtechMedical Devices

Karyopharm Therapeuticskaryopharm.com in 𝕏Dec 2022

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)in Reshma Rangwala(Executive Officer)in Richard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in

Co-investorsAvoro Capital Advisors Foresite Capital RA Capital

Korsuvakorsuva.com

KORSUVA is a prescription medicine that treats moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis.

BiotechDigital HealthHealthtechMedical Devices

Lantheuslantheus.com in 𝕏

Lantheus is a radiopharmaceutical company that develops, manufactures, and commercializes radiodiagnostics and radiotherapeutics for cancer detection, treatment and monitoring, as well as precision diagnostics for non-oncologic diseases.

BiotechHealthtechMedical DevicesNorth Billerica, US

Lyricalyrica.com

Lyrica is a pharmaceutical product used to manage fibromyalgia, a chronic condition characterized by widespread pain and fatigue.

BiotechHealthtechMedical Devices

Nanobiotixnanobiotix.com in 𝕏

Nanobiotix develops physics-based nanotherapeutics for cancer treatment, applying nanotechnology to expand therapeutic options for oncology patients.

BiotechDeep TechMedical Devices

Co-investorsKarista Seventure Partners Jefferies

Opkoopko.com

OPKO Health is a fully integrated healthcare company developing multispecific therapies for serious diseases including cancers and infectious diseases, and operates BioReference Laboratories, a clinical reference laboratory serving approximately 11 million patients annually in the U.S.

BiotechDigital HealthHealthtechMedical DevicesMiami, US

Gary Nabelin

Orenitramorenitram.com

Orenitram is a prescription oral medication containing treprostinil, indicated to treat pulmonary arterial hypertension (PAH) by slowing disease progression and improving exercise capacity in adults.

BiotechHealthtech

Regenx Biosciencesregenxbio.com in 𝕏

REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies.

BiotechHealthtechRockville, US

Kenneth T. Mills(Executive Officer, Director)

BoardJohn Daniel Kiser(Director)Allan M. Fox(Director)Benjamin Auspitz(Director)Donald J. Hayden, Jr.(Director)

Co-investorsF-Prime Capital Foothill Ventures Venrock

Relistorrelistor.com

RELISTOR is a prescription medication containing methylnaltrexone bromide that treats opioid-induced constipation in adults with chronic pain or advanced illness.

BiotechDigital HealthHealthtechMedical Devices

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Jan 2017

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)in Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

Board Edward T. Mathers(Director)in Jonathan Silverstein(Director)in Neil Exter(Director)in

Co-investorsForesite Capital New Enterprise Associates (NEA)Pfizer Venture Investments Wellington Management OrbiMed Third Rock Ventures

Seysaraseysara.com

SEYSARA is a prescription medication with a patient co-pay assistance program (Almirall Advantage) that offers savings on retail and network pharmacy purchases.

BiotechHealthtech

Sperosperotx.com in

Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps.

BiotechHealthtechCambridge, US

Co-investorsAtlas Venture The Kraft Group

Suneva Medicalsunevamedical.com inJan 2014 · $35M

A company offering regenerative and aesthetic medical products for facial, breast, and body treatments across all stages of life.

HealthtechMedical DevicesSan Diego, US

Nicholas L. Teti, Jr.(Executive Officer, Director)Joseph A. Newcomb(Executive Officer)Stewart M. Brown(Executive Officer)in

BoardClarke B. Futch(Director)Paul J. Hadden(Director)Todd C. Davis(Director)

Co-investorsBioBrit Essex Woodlands Healthcare Partners Polaris Partners

Tenapanoribsrela.com

IBSRELA is a prescription medication containing tenapanor designed to treat irritable bowel syndrome with constipation (IBS-C) in adults by reducing constipation and abdominal pain.

BiotechHealthtechMedical Devices

Tg Therapeuticstgtherapeutics.com in 𝕏

TG Therapeutics is a biopharmaceutical company focused on developing treatments for cancer patients.

BiotechHealthtechMedical Devices

Michael S. Weiss(CEO)

Theravance Biopharmatheravance.com

Theravance Biopharma develops FDA-approved pharmaceutical treatments, including YUPELRI for chronic obstructive pulmonary disease (COPD) maintenance treatment.

BiotechHealthtechMedical Devices

Rick E Winningham(Chief Executive Officer)in Rhonda F. Farnum(Senior Vice President, Commercial and Medical Affairs and Chief Business Officer)inBrett A. Grimaud(Senior Vice President, General Counsel and Secretary)inStuart Knight(Senior Vice President, IT&I and Chief Information Officer)Aine Miller(Senior Vice President, Development and Head of Ireland Office)Stacy Pryce(Senior Vice President and Chief Strategy Officer)in

Trelegy Elliptatrelegy.com

TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults.

Biotech

Uniqureuniqure.com in 𝕏

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

Matthew Kapusta in

Co-investorsAdvent Life Sciences ALS Investment Fund Foresite Capital Ridgeback Capital Forbion

Vafseovafseo.com

Vafseo (vadadustat) is a once-daily oral prescription medicine that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months.

BiotechHealthtech

XOMAxoma.com inacquired by Ligand · Jul 2026 · $739M

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.

BiotechFintech

Owen Hughes(Chief Executive Officer)inJeffrey Trigilio(Chief Financial Officer)in Brad Sitko(Chief Investment Officer)inMaricel Montano(Chief Legal Officer)

Co-investorsLigand Pharmaceuticals Sanderling Ventures

Zevrazevra.com in 𝕏

Zevra Therapeutics develops and commercializes rare disease treatments, including therapies for Niemann-Pick disease type C and urea cycle disorders.

BiotechHealthtechMedical Devices

Neil McFarlanein

Zolgensmazolgensma.com

ZOLGENSMA is a gene replacement therapy that delivers a working SMN gene to treat spinal muscular atrophy (SMA), a rare genetic disease affecting motor nerve cells.

BiotechDigital HealthHealthtechMedical Devices

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Acorda Therapeutics IncAdamas PharmaceuticalsAkebiaBexacatBeyonttraCara TherapeuticsCetrotideCopiktratmDyaxElobixibatErivedgeEsperionFampyraGenfitHeidelbergHemgenixInavirJnj 1900 Nbtxr3La Jolla Pharmaceutical CompanyLexivaLiquidiaLumifyModeysoMovantikOraceaPortolaProgenics PharmaceuticalsQs 21 Adjuvant Including ShingrixRaptorRelypsaRezurockRuxienceTearScienceTheracosTlx250 CdxTrumenbaVimpatXipere Et Al

Exits · 13

9 IPOs · 4 acquisitions · showing 12

ADC Therapeutics SANYSE: ADCTAgenusNASDAQ: AGENApnimedNASDAQ: APMDAptevo TherapeuticsNASDAQ: APVOAtara BiotherapeuticsNASDAQ: ATRACoherus BiosciencesNASDAQ: CHRSNektar TherapeuticsNASDAQ: NKTRRedHill Biopharma LtdNASDAQ: RDHLSpero TherapeuticsNASDAQ: SPROProgenics Pharmaceuticalsacq. by Lantheus HoldingsRelypsaacq. by Galenica (Vifor Pharma)XOMAacq. by Ligand

Portfolio news

latest coverage across their companies

Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout

Lantheus · stocktitan.net · Sep 8, 2026

AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside

Agenus · simplywall.st · Aug 15, 2026

The Startup Behind The Pill For Sleep Apnea Raises $192 Million In IPO

Apnimed · forbes.com · Jul 31, 2026

Spero Therapeutics licenses SP001, raises $105M | SPRO 8-K Filing

Spero Therapeutics · stocktitan.net · Jul 14, 2026

Spero Therapeutics licenses SP001, raises $105M | SPRO 8-K Filing

Spero · stocktitan.net · Jul 14, 2026

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress - BioSpace

Atara Biotherapeutics · biospace.com · May 13, 2026

Fund performance · per public LP disclosures

as of Jun 2024

Fund	Vintage	Committed	Net IRR	TVPI	DPI
HealthCare Royalty Partners III, L.P.LPs: Florida State Board of Administration	2007	—	9.1%	1.27x	1.27x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

Frequently asked questions

How many investments has HEALTHCARE ROYALTY PARTNERS made?: HEALTHCARE ROYALTY PARTNERS has 81 tracked investments, 13 of which have exited, including 1 dated in the last 24 months.
What sectors does HEALTHCARE ROYALTY PARTNERS focus on?: HEALTHCARE ROYALTY PARTNERS focuses on Biotech, Healthtech.
Where is HEALTHCARE ROYALTY PARTNERS located?: HEALTHCARE ROYALTY PARTNERS is headquartered in New York, US.
Who does HEALTHCARE ROYALTY PARTNERS co-invest with?: HEALTHCARE ROYALTY PARTNERS most often shares deals with Foresite Capital, New Enterprise Associates (NEA), Ridgeback Capital, among 44 tracked co-investors.

Images

Similar investors

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$500K – $50M

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.

$50K – $12.7M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M